Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients-Reference-Cited by-同舟云学术

Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients

Published:2014-11-12 Issue:10 Volume:136 Page:2352-2360
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Jiang Huanhuan¹²³,Gebhardt Christoffer¹²,Umansky Ludmila⁴,Beckhove Philipp⁴,Schulze Torsten J.⁵,Utikal Jochen¹²,Umansky Viktor¹²

Affiliation:

1. Skin Cancer Unit; German Cancer Research Center (DKFZ); Heidelberg Germany

2. Department of Dermatology, Venereology and Allergology; University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg; Mannheim Germany

3. Department of Obstetrics and Gynecology, Center for Reproductive Medicine; The First Hospital Affiliated to Anhui Medical University; Hefei China

4. Department of Translational Immunology; German Cancer Research Center (DKFZ); Heidelberg Germany

5. Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; German Red Cross Blood Service Baden Württemberg-Hessen; Mannheim Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference49 articles.

1. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?;Erdmann;Int J Cancer,2013

2. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma”;Pflugfelder;J Dtsch Dermatol Ges,2013

3. Human T cell responses against melanoma;Boon;Annu Rev Immunol,2006

4. Immunotherapy for advanced melanoma: fulfilling the promise;Gogas;Cancer Treat Rev,2013

5. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients;Ott;Clin Cancer Res,2013

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP;Frontiers in Immunology;2024-01-18

2. Clinical and Immunologic Features of Germline Pathogenic Variant–Positive Patients with Melanoma;Clinical Cancer Research;2023-11-30

3. IL-17 promotes melanoma through TRAF2 as a scaffold protein recruiting PIAS2 and ELAVL1 to induce EPHA5;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2023-10

4. Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications;Advances in Cancer Biology - Metastasis;2023-10

5. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs;OncoImmunology;2023-08-13